Tissue microarray-chip featuring computerized immunophenotypical characterization more accurately subtypes ampullary adenocarcinoma than routine histology

Table 3 Patient characteristics

Patient characteristics	n
Age, mean ± SD (yr)	72.9 ± 8.1
M/F	11/10
BMI, mean ± SD (kg/m2)	22.9 ± 3.9
ASA I, n (%)	3 (14.2)
ASA II, n (%)	6 (28.6)
ASA III, n (%)	11 (52.4)
ASA IV, n (%)	1 (4.8)
Comorbidity, n (%)	16 (76.1)
Cardiovascular disease, n (%)	6 (28.6)
COPD, n (%)	6 (28.6)
Hypertension, n (%)	10 (47.6)
Diabetes mellitus, n (%)	3 (14.2)
Symptomatic, n (%)	12 (57.1)
Jaundice, n (%)	7 (58.3)
Pain, n (%)	3 (25.1)
Nausea or Vomiting, n (%)	1 (8.3)
Loss of weight, n (%)	1 (8.3)
Placement of PTBD or biliary endoprothesis, n (%)	4 (33.3)
CA 19.9, mean ± SD (U/mL)	37.1 ± 53.2
Neoadjuvant therapy, n (%)	0 (0)

ASA: American Society of Anesthesiologists; COPD: Chronic obstructive pulmonary disease; PTBD: Percutaneous transhepatic biliary drainage.